Neurodegenerative Disease Therapeutics Industry Data Book | Forecast 2030
Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030
Grand View Research’s neurodegenerative disease therapeutics industry data book is a collection of market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, macro-environmental analyses studies. Within the purview of the database, such information is systematically analyzed and provided in the form of summary presentations and detailed outlook reports on individual areas of research.The following data points will be included in the final product offering in two reports and one sector report overview.
Access the Global Neurodegenerative Disease Therapeutics Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies.
Parkinson’s Disease Treatment Market Report Highlights
The global Parkinson’s disease treatment market size is expected to reach USD 11.98 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 12.1% from 2022 to 2030.
- By drug class, the Carbidopa-Levodopa segment held the largest revenue share in 2021 due to the high prevalence of PD and easy drug availability for the disease treatment
- The retail pharmacy distribution channel segment dominated the global industry in 2021
- This is due to the easy availability of PD drugs in well-established retail pharmacy chains including Walgreens and Walmart
- Asia Pacific is expected to be the fastest-growing region during the forecast period due to the entry of new products into the market
- In June 2020, Ono Pharmaceutical Co., Ltd. received manufacturing and marketing approval for Ongentys to treat patients with PD in Japan
Alzheimer's Therapeutics Market Report Highlights
The global Alzheimer’s therapeutics market size is expected to reach USD 15.6 billion by 2030, according to a new study by Grand View Research Inc. It is expected to expand at a CAGR of 16.2% from 2022 to 2030.
- By product, the cholinesterase inhibitors segment held the largest revenue share in 2021 as it is the current standard of care. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc. for the treatment of patients with AD
- Pipeline drugs are anticipated to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected launch during the forecast period. Biogen’s product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating AD, is currently in phase 3 clinical trials
- The hospital pharmacy end-user segment dominated the market in 2021 owing to the high hospitalization rate. According to Alzheimer’s Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer’s have at least one hospital discharge annually
Order your copy of the Free Sample of “Neurodegenerative Disease Therapeutics Industry Data Book - Parkinson’s Disease Treatment and Alzheimer's Therapeutics Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030” Data Book, published by Grand View Research
Competitive Landscape
Key players operating in the Neurodegenerative Disease Therapeutics industry are –
- Cerevel Therapeutics
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc. (GSK)
- AbbVie, Inc.
- Supernus Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Adamas Pharmaceuticals, Inc.
- Biogen
- AC Immune
- DAIICHI SANKYO COMPANY, LIMITED
- Johnson & Johnson Services Inc.
- TauRx Pharmaceuticals Ltd.
- Hoffmann La Roche Ltd.
Grand View Research’s Neurodegenerative Disease Therapeutics Industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.
Check out more Industry Data Books, published by Grand View Research
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
The global Rare Neurodegenerative Disease Treatment Market research report, published by Value Market Research, is designed to offer various market framework such as market size, portion, trends, growth path, value and factors that impact the current market dynamics over the forecast period 2020-2027.
Most importantly, this report also provides the latest significant strategies adopted by major players along with their market share.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the rare neurodegenerative disease treatment market include Allergan Plc, Bayer AG, F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Rare Neurodegenerative Disease Treatment Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/rare-neurodegenerative-disease-treatment-market/download-sampleMarket DynamicsThe rise in prevalence and increase in demand for newer drugs to treat rare neurological disorders has led to an increase in research & development efforts followed by introducing innovative neurological disorder drugs.
In addition, an increase in demand for neurological disorder drugs for the treatment of Alzheimer’s disease and Parkinson’s disease and a rise in competition between major players are likely to boost the growth of the market.
However, the cost of neurological disorder treatment is considerably high, owing to the large quantity of antiepileptic, anticholinergic, and hypnotic & sedatives required.
This causes problems with movement (Ataxia), or mental functioning (dementia).
The overall Global Neurodegenerative Disease Market is expected to grow at a significant compound CAGR rate of 6.8% from USD 32.65 billion in 2018 to USD 55.26 billion in 2026.
Moreover, increasing occurrence of neurological disorders is providing ample of opportunities.Global Neurodegenerative Disease: Key SegmentsBy Indications: - Amongst indications, Alzheimer’s disease segment captured the largest market share of the global market due to Alzheimer's disease (AD) is the most widely neurodegenerative disease.
Hallmark pathohistological findings of AD include widespread neuronal degeneration, extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT) different lines of evidence indicate that AD grows primarily as the result of an amyloid cascade.By Drug class: - Amongst Drug class, SSRIs segment captured the largest market share of the global market due to Sertraline (Zoloft) is a particular serotonin reuptake inhibitor (SSRI) that is generally prescribed as an antidepressant and proposed as a potential first-line medication to treat individuals with major depression.
North America region dominated the Neurodegenerative Disease market owing to the development of medical infrastructure and half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities and technological advancement.
Additionally, there are a large number of patients who go undetected.
